Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of CHF 4226 pMDI 2 µg Once Daily on 24-hour Trough FEV1 in Moderate or Severe Persistent Asthma
2006-005689-38Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of carmoterol in asthma (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Trough FEV1 at Day 28 (mean of 23 and 24 hours). Started Jan 2007; status: completed.
02
Drugs
carmoterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2006-005689-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005689-38.